The present study investigated the anti-atherosclerotic activity of lacidipine, a calcium antagonist with antioxidant properties in apoE-deficient mice. These mice show widespread vascular lesions which closely resemble the inflammatory-fibrous plaques seen in humans in atherosclerosis. Mice were fed a Western-type diet (WTD), and treated for 8 weeks with either vehicle or lacidipine at 3 or 10 mg/kg/day. In parallel with histological studies of atherosclerotic lesions in the aorta, functional studies on vascular acetylcholine (ACh) reactivity and analysis of voltammetric levels of nitric oxide (NO) were performed. Recent work has suggested that dihydropyridines (DHPs) modulate vascular relaxation via an increase in the release of NO. Lacid...
BACKGROUND AND PURPOSE: Calcium-channel blockers (CCBs) reduce systolic blood pressure and stroke-re...
Type 1 diabetes is an immuno-inflammatory condition which increases the risk of cardiovascular disea...
Background and Purpose - Calcium-channel blockers (CCBs) reduce systolic blood pressure and stroke-r...
Atherosclerosis is the major form of heart disease in Western countries. Atherosclerosis is a slowly...
WOS: 000284731000001PubMed ID: 20709189The antiatherosclerotic effect of lacidipine has been attribu...
1. Cholesterol esterification and accumulation in the arterial wall is a hallmark of atherogenesis. ...
Lacidipine, a third generation dihydropyridine calcium antagonist, has demonstrated pronounced anti-...
AIM: To evaluate the effect of lacidipine on the major processes of atherogenesis. METHODS: Cell-cul...
We have investigated the activity of the calcium antagonist lacidipine in male hamsters fed an ather...
It has been known for some time that calcium antagonists demonstrate antiatherosclerotic activity. T...
The in vivo antiatherogenic activity of the calcium antagonist lacidipine was investigated in arteri...
The in vivo antiatherogenic activity of the calcium antagonist, lacidipine, was investigated in two ...
Endothelium-dependent vasorelaxation is defective in hypertensive rats, especially in conduit arteri...
Impaired endothelial nitric oxide synthesis (eNOS) / nitric oxide (NO) pahtway induce the atherogene...
The markers of the bioavailability of NO (endothelium-dependent relaxation to acetylcholine and cycl...
BACKGROUND AND PURPOSE: Calcium-channel blockers (CCBs) reduce systolic blood pressure and stroke-re...
Type 1 diabetes is an immuno-inflammatory condition which increases the risk of cardiovascular disea...
Background and Purpose - Calcium-channel blockers (CCBs) reduce systolic blood pressure and stroke-r...
Atherosclerosis is the major form of heart disease in Western countries. Atherosclerosis is a slowly...
WOS: 000284731000001PubMed ID: 20709189The antiatherosclerotic effect of lacidipine has been attribu...
1. Cholesterol esterification and accumulation in the arterial wall is a hallmark of atherogenesis. ...
Lacidipine, a third generation dihydropyridine calcium antagonist, has demonstrated pronounced anti-...
AIM: To evaluate the effect of lacidipine on the major processes of atherogenesis. METHODS: Cell-cul...
We have investigated the activity of the calcium antagonist lacidipine in male hamsters fed an ather...
It has been known for some time that calcium antagonists demonstrate antiatherosclerotic activity. T...
The in vivo antiatherogenic activity of the calcium antagonist lacidipine was investigated in arteri...
The in vivo antiatherogenic activity of the calcium antagonist, lacidipine, was investigated in two ...
Endothelium-dependent vasorelaxation is defective in hypertensive rats, especially in conduit arteri...
Impaired endothelial nitric oxide synthesis (eNOS) / nitric oxide (NO) pahtway induce the atherogene...
The markers of the bioavailability of NO (endothelium-dependent relaxation to acetylcholine and cycl...
BACKGROUND AND PURPOSE: Calcium-channel blockers (CCBs) reduce systolic blood pressure and stroke-re...
Type 1 diabetes is an immuno-inflammatory condition which increases the risk of cardiovascular disea...
Background and Purpose - Calcium-channel blockers (CCBs) reduce systolic blood pressure and stroke-r...